Furthermore, COX16, COX17, and SLC16A2 may represent attractive therapeutic targets for HPV+ HNSCC that warrant further exploration, especially considering that treatment with specific inhibitors may phenocopy the effects of low expression of these metabolic genes. The gene discussed is SLC16A2; the disease is head and neck squamous cell carcinoma.